Both in Biotechnology
Recursion Pharmaceuticals vs Vir Biotechnology
Over the past year RXRX returned −22.4% and VIR returned +124.2%; their daily moves had a correlation of 0.47.
RXRX −22.4% VIR +124.2%Growth of $1, one year, split-adjusted
| Metric | RXRX | VIR |
|---|---|---|
| Price | $3.88 | $11.77 |
| Market cap | $2.32B | $1.99B |
| Today | +5.43% | +4.90% |
| 1 month | −16.2% | +1.5% |
| 6 months | +13.1% | +14.4% |
| Year to date | −5.1% | +95.2% |
| 1 year | −28.7% | +110.2% |
| Revenue growth (YoY) | +258.5% | +19582.5% |
| Gross margin | 45.9% | 100.0% |
| Net margin | −641.6% | 33.5% |
| P/E (TTM) | — | — |
| Price / sales | 34.0× | 6.6× |
| Net cash | $538.0M | $532.7M |
| Dividend yield | — | — |
| Volatility (60d) | 95.9% | 52.3% |
| Short % of float | 37.5% | 12.3% |
| Next earnings | — | — |
Shading marks the stronger figure where one clearly exists (lower is better for valuation and volatility).